Germany Patient Support Programs (PSP) market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of 8.1% for the year 2022-2030. The major factor responsible for the Germany Patient Support Programs (PSP) market is the increasing demand for patient-centric care for managing diseases in Germany. The market is segmented by functionality outlook, therapeutic outlook, application outlook, and end user. Some of the major PSP operators in the Germany Patient Support Programs (PSP) market are Ashfield Engage, CEBIS International, and Vitartis Medical Service.
The Germany Patient Support Programs (PSP) market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of 8.1% during the forecast period. The federal government will boost its contribution to the healthcare budget by $2.14 Bn, raise insurance premiums by 0.3 %age points, and provide a $1.07 Bn interest-free loan to fund mandatory health insurance. The GKV-Finanzstabilisierungsgesetz (GKV-FinStG) aims to stabilize the financial position of statutory health insurance (GKV) in order to cover an expected $18.23 Bn deficit for 2023. In order to maintain constant contributions, mandatory health insurance in Germany will receive an additional $7.50 Bn from taxpayers in 2022. In 2022, the amount the government will spend on health insurance will increase to a total of $30.56 Bn.
Patient support programs (PSPs) enhance the care patients receive from their healthcare team by providing them with information, training, education, and practical and emotional support. This gives patients the tools they need to effectively manage their conditions on their own. PSPs are currently a crucial instrument for collecting data for pharmacovigilance and enhancing patient safety. Smaller and medium-sized corporations in Germany have invested in these programs, and nearly all major pharmaceutical companies offer some level of PSPs for drugs that treat chronic illnesses. PSPs are a common component of the business for individuals involved in the treatment of rare diseases. Patient support programs provided by pharmaceutical companies in Germany are typically designed to offer additional support to patients who have been prescribed a particular medication. Some examples of patient support programs provided by pharmaceutical companies in Germany include patient education and counseling, and medication support- Pharmaceutical firms may offer patient assistance programs, such as co-pay assistance programs or free medicine programs for those who satisfy certain requirements, to help patients manage the expense of their medications. Adherence support, disease management, monitoring, and patient advocacy and support groups are some other PSPs offered by pharmaceutical companies in Germany.
Market Growth Drivers
In Germany, there is an increasing emphasis on patient-centered care, which emphasizes offering individualized care that caters to the specific needs of individual patients. By giving patients the tools and assistance, they need to manage their conditions, patient support programs can contribute to the success of this strategy by fostering the Germany PSP market growth.
Some patients might not be aware that patient support programs are offered to them or they might not be aware of the advantages these programs can provide. The adoption of these programs can be hampered by this ignorance. For smaller pharmaceutical businesses in particular, creating and implementing patient care programs can be expensive. These expenses might be passed on to patients or healthcare providers, which might prevent these initiatives from being adopted in Germany.
Major Patient Support Programs in Germany
|Patient Support Programs||Focus Area||Pharma Sponsor|
|Herzstolpern - Achten Sie auf Ihren Rhythmus (Heart stumbling - Watch your rhythm)||Atrial Fibrillation||Bristol Myers Squibb Pfizer|
|Aktiv mit Rheuma (Active with rheumatism)||Rheumatoid Arthritis||Bristol Myers Squibb|
|Aktiv mit Psoriasis-Arthritis (Active with psoriasis arthritis)||Psoriatic Arthritis||Bristol Myers Squibb|
|AbbvieCare Support Program||Chronic Inflammatory Diseases||Abbvie|
|KabiCare||Chronic Diseases||Fresenius Kabi|
|Gesünder unter 7 Plus (Healthier under 7 plus)||Diabetes and Cholesterol||Sanofi|
The European Medicine Agency’s (EMA) good practice guidelines for pharmacovigilance address legal requirements applicable to marketing authorization holders (MAHs) for the management and reporting of safety data arising in PSPs that involve direct interactions with patients and caregivers for the purpose of helping to manage a patient’s medication and disease outcomes (for example, adherence, awareness, and education) or providing HCPs with support for their patients.
In Germany, the PSPs are specifically tailored to a particular product that is provided to patients and/or physicians free of charge and can qualify as benefits that could fall under the prohibition of Section 7 HWG (heilmittelwerbegesetz).
The FSA (Association for the Voluntary Self-Regulation of the Pharmaceutical Industry) Transparency Code obliges all FSA member companies to publish their direct and indirect services provided to doctors, healthcare professionals, and healthcare organizations. This includes services related to research and development as well as donations and other unilateral services in connection with advanced training courses, services, and consultancy fees.
The permissibility of PSPs has been thoroughly assessed and reconsidered by the FSA, which lead to the FSA Code of Conduct Healthcare Professionals, according to which, amongst other requirements, such measures ensure the correct application and use of the pharmaceutical product must follow a medical rationale to be assessed and determined by the medical department of the company.
1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
18.104.22.168 Product Applications and Services
22.214.171.124 Recent Developments
126.96.36.199 Partnerships Ecosystem
188.8.131.52 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Functionality Outlook
By Therapeutic Area Outlook
By Application Outlook
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses